STOCK TITAN

BioVie Inc - BIVI STOCK NEWS

Welcome to our dedicated news page for BioVie (Ticker: BIVI), a resource for investors and traders seeking the latest updates and insights on BioVie.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BioVie's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BioVie's position in the market.

Rhea-AI Summary
BioVie Inc. (NASDAQ: BIVI) announces a public offering of common stock to raise funds for working capital and general corporate purposes. ThinkEquity LLC will act as the placement agent for the offering. The Company plans to use the net proceeds for operational needs. The offering is subject to market conditions, and the actual size and terms are uncertain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
-
Rhea-AI Summary
BioVie Inc. announces promising data from Phase 2a trial in Parkinson’s Disease and Phase 3 trial in Alzheimer’s Disease. NE3107 shows significant improvements in non-motor symptoms and motor control in Parkinson’s Disease patients, while potentially realigning physiological processes in Alzheimer’s Disease patients. The upcoming presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases 2024 will highlight these findings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
52.42%
Tags
none
-
Rhea-AI Summary
BioVie Inc. (NASDAQ: BIVI) is participating in the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13-14, 2024. The company's management team will be involved in the virtual event, showcasing its innovative drug therapies for advanced liver disease and neurological disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.83%
Tags
conferences
Rhea-AI Summary
RedChip Companies will air interviews with bioAffinity Technologies, Inc. (BIAF) and BioVie, Inc. (BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV. BioAffinity Technologies is an emerging player in early-stage cancer diagnosis and treatment, with a focus on lung cancer detection. The company's flagship product, CyPath® Lung, has shown high sensitivity, specificity, and accuracy in detecting early-stage lung cancer. The company also holds extensive U.S. and international patents and has strong insider ownership at 39%. BioVie, Inc. is a clinical-stage company developing therapies for Alzheimer's, Parkinson's, refractory ascites, and HRS-AKI. The company recently reported positive trending data from a Phase 3 trial in Alzheimer's and has plans to launch Phase 3 trials in 2024 for Alzheimer's, Parkinson's, and Ascites.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.79%
Tags
none
-
Rhea-AI Summary
RedChip Companies will air interviews with bioAffinity Technologies, Inc. (BIAF) and BioVie, Inc. (BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV. BioAffinity Technologies is an emerging player in early-stage cancer diagnosis and treatment, with a focus on lung cancer detection. The company's flagship product, CyPath® Lung, has shown high sensitivity, specificity, and accuracy in detecting early-stage lung cancer. The company also holds extensive U.S. and international patents and has strong insider ownership at 39%. BioVie, Inc. is a clinical-stage company developing therapies for Alzheimer's, Parkinson's, refractory ascites, and HRS-AKI. The company recently reported positive trending data from a Phase 3 trial in Alzheimer's and has plans to launch Phase 3 trials in 2024 for Alzheimer's, Parkinson's, and Ascites.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.4%
Tags
none
-
Rhea-AI Summary
RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, December 30, at 7 p.m. Eastern Time (ET). Genetic Technologies is executing a B2B commercialization strategy for its flagship geneType multi-risk test covering various diseases, with a global market expected to reach $4.6 billion by 2025. BioVie is a clinical-stage company developing transformative therapies for Alzheimer's, Parkinson's, and liver diseases, with positive trending data from a Phase 3 trial in AD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
none
Rhea-AI Summary
RedChip Companies will air interviews with Genetic Technologies Limited (NASDAQ:GENE) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, December 30, at 7 p.m. Eastern Time (ET). Genetic Technologies is executing a B2B commercialization strategy for its flagship geneType multi-risk test covering various diseases, with a global market expected to reach $4.6 billion by 2025. BioVie is a clinical-stage company developing transformative therapies for Alzheimer's, Parkinson's, and liver diseases, with positive trending data from a Phase 3 trial in AD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
none
-
Rhea-AI Summary
RedChip Companies will air interviews with Rail Vision (NASDAQ:RVSN) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show on Bloomberg TV this Saturday, December 23, at 7 p.m. Eastern Time (ET). Rail Vision is a company at the forefront of an evolution in train safety, providing AI-based detection systems for obstacle identification on and near tracks. Knorr Bremse, a key strategic investor, has invested $25M across two investment cycles. BioVie is a clinical-stage company developing transformative therapies for neurodegeneration and liver disease, with positive trending data from a Phase 3 trial in Alzheimer's and Parkinson's. The company plans to launch Phase 3 trials in 2024 and has multiple other efforts underway that may create additional catalysts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
-
Rhea-AI Summary
RedChip Companies will air interviews with Rail Vision (NASDAQ:RVSN) and BioVie, Inc. (NASDAQ:BIVI) on The RedChip Small Stocks Big Money® Show on Bloomberg TV this Saturday, December 23, at 7 p.m. Eastern Time (ET). Rail Vision is a company at the forefront of an evolution in train safety, providing AI-based detection systems for obstacle identification on and near tracks. Knorr Bremse, a key strategic investor, has invested $25M across two investment cycles. BioVie is a clinical-stage company developing transformative therapies for neurodegeneration and liver disease, with positive trending data from a Phase 3 trial in Alzheimer's and Parkinson's. The company plans to launch Phase 3 trials in 2024 and has multiple other efforts underway that may create additional catalysts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
none
Rhea-AI Summary
BioVie Inc. (NASDAQ: BIVI) announced positive analysis of unblinded, topline efficacy data from its Phase 3 clinical trial of NE3107 in the treatment of mild to moderate Alzheimer’s Disease. The trial showed NE3107’s treatment advantage over placebo to potentially be equal to or greater than data reported from clinical trials for the approved medications for AD without the associated safety concerns. The trial started during the COVID-19 pandemic, enrolling 439 patients through 39 sites. The trial identified significant deviations from protocol and Good Clinical Practice (GCP) violations at 15 sites, leading to exclusions and referral to the U.S. Food and Drug Administration (FDA) Office of Scientific Investigations (OSI) for further action. After exclusions, 81 patients remained in the Modified Intent to Treat (MITT) population, 57 of whom were in the Per-Protocol population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-60.72%
Tags
clinical trial
BioVie Inc

Nasdaq:BIVI

BIVI Rankings

BIVI Stock Data

75.36M
15.96M
59.65%
6.17%
2.58%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Carson City

About BIVI

biovie inc. (otc pink: bivi) is developing novel drug therapies for life-threatening complications of chronic liver disease. our initial target is ascites, which can occur in patients with advanced cirrhosis due to hepatitis, nash (non-alcoholic steatohepatitis), or alcoholism. ascites affects about 100,000 americans and carries an estimated 40% mortality rate within two years of being diagnosed. the company’s new drug candidate biv201 is about to enter a phase 2 clinical trial in the us. it’s based on a drug (terlipressin) not yet available in the us, but approved in about 40 countries for treating related complications of liver cirrhosis. the fda has never approved a drug to treat ascites and there is a significant unmet medical need for our novel therapy, which has orphan drug status. biovie has attracted funding from strategic investors including aspire capital, cuong do, the global strategy lead for samsung, and hari kumar, founder of adheron therapeutics which he sold to roche fo